[Retracted] Efficacy of Neoadjuvant Chemotherapy with Epirubicin and Cyclophosphamide and Weekly Paclitaxel and Trastuzumab in Human Epidermal Growth Factor Receptor 2–Positive Breast Carcinoma: A Real-World Study

Table 1

Associations of clinical characteristics with pCR in univariate analysis.

	Non-pCR ()		pCR ()		value
		%		%
Age (year)					0.182
≤35	24	13.0	3	6.1
>35	161	87.0	46	93.9
Menopausal status					0.527
Premenopausal	100	54.1	24	49.0
Postmenopausal	85	45.9	25	51.0
cT stage					0.389
cT1–2	124	67.0	36	73.5
cT3–4	61	33.0	13	26.5
cN stage					0.07
cN0	94	50.8	32	65.3
cN1–3	91	49.2	17	34.7
Grade					0.729
G1–2	41	22.2	12	24.5
G3	144	77.8	37	75.5
ER					0.472
Positive	105	56.8	25	51.0
Negative	80	43.2	24	49.0
PR					0.949
Positive	84	45.4	22	44.9
Negative	101	54.6	27	55.1
HR					0.854
Positive	82	44.3	21	42.9
Negative	103	55.7	28	57.1
Ki-67					0.791
>30%	87	47.0	22	44.9
≤30%	98	53.0	27	55.1
Molecular subtype					0.607
Luminal B/HER2+	102	55.1	25	51.0
Nonluminal/HER2+	83	44.9	24	49.0
Trastuzumab					0.004
Yes	64	34.6	28	57.1
No	121	65.4	21	42.9